The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Piper Sandler on November 11, 2025. The analyst firm set a price target for $72.00 expecting ARCT to rise to within 12 ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Arcturus Therapeutics' interim Phase 2 CF data fell short of expectations, leading to a justified ~50% stock drop and ongoing caution. ARCT-032 showed no meaningful FEV1 improvement in CF patients, ...

SAN DIEGO, October 28, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Arcturus Therapeutics (NASDAQ:ARCT) traded lower on Friday after Citi downgraded the San Diego, California-based biotech, citing mid-stage data the company posted this week for ARCT-032, a messenger ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Arcturus Therapeutics (NASDAQ:ARCT) is gearing up to announce its quarterly earnings on Monday, 2025-11-10. Here's a quick overview of what investors should know before the release. Analysts are ...

Arcturus Therapeutics Holdings recently saw its consensus analyst price target lowered from $69.89 to $65.88, reflecting a modest dialing back of expectations about its future share value. This ...

As you explore The Slums in both Chapter 4 and Chapter 6, you may run into a shop on the right side of the alleys where a robot named Grandma can be found knitting. This robot will tell you that she ...